This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PTI-NC-733

Proteostasis Therapeutics, Inc.

Drug Names(s): PTI NC 733, PTI-428+PTI-801+PTI-808

Description: PTI-NC-733 is a proprietary triple combination therapy consisting of PTI-801 (corrector), PTI-808 (potentiator), and PTI-428 targeting the cystic fibrosis transmembrane conductance regulator (CFTR) protein.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug